<SEC-DOCUMENT>0001178913-24-002658.txt : 20240815
<SEC-HEADER>0001178913-24-002658.hdr.sgml : 20240815
<ACCEPTANCE-DATETIME>20240815162009
ACCESSION NUMBER:		0001178913-24-002658
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240815
FILED AS OF DATE:		20240815
DATE AS OF CHANGE:		20240815

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MediWound Ltd.
		CENTRAL INDEX KEY:			0001593984
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36349
		FILM NUMBER:		241212693

	BUSINESS ADDRESS:	
		STREET 1:		42 HAYARKON STREET
		CITY:			YAVNE
		STATE:			L3
		ZIP:			8122745
		BUSINESS PHONE:		97289324010

	MAIL ADDRESS:	
		STREET 1:		42 HAYARKON STREET
		CITY:			YAVNE
		STATE:			L3
		ZIP:			8122745
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2431877.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 24.6.1.5240
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C.&#160; 20549<br>
        ______________________</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FORM 6-K</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT&#160;OF FOREIGN PRIVATE ISSUER</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Pursuant to Rule 13a-16 or 15d-16 of the<br>
        Securities Exchange Act of 1934</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">For the month of August 2024</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Commission File Number: 001-36349</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-size: 16pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">MediWound Ltd.</font><br>

        <hr align="center" style="height: 1px; width: 30%; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;">(Translation of registrant&#8217;s name into English)</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">42 Hayarkon Street</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Yavne, 8122745 Israel</div>
      <div style="text-align: center; line-height: 1.25;">&#160;(Address of principal executive offices)</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Form 20-F &#9746;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">Form
          40-F &#9744;</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 36pt; line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
        101(b)(1):&#160; &#9744;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 36pt; line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
        101(b)(7):&#160; &#9744;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXPLANATORY NOTE</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On August 15, 2024, MediWound Ltd. (the &#8220;Company&#8221;) issued a press release entitled &#8220;MediWound Announces U.S. Food
        and Drug Administration Approval of NexoBrid<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> for the Treatment of Pediatric Patients with Severe Thermal Burns&#8221;. A copy of this press release is attached to this Report of Foreign Private Issuer on Form 6-K (this &#8220;Form 6-K&#8221;) as Exhibit
        99.1.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The content of this report on Form 6-K (including the information contained in Exhibit 99.1, but excluding quotes
        of senior management of the Company), is hereby incorporated by reference into the Company&#8217;s Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021
        August 9, 2022 and August 15, 2023&#160;(Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697 and 333-273997, respectively) and on Form F-3 filed with the SEC on May 25, 2022 and March 31, 2023
        (Registration Nos. 333-265203 and 333-268297, respectively).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">SIGNATURE</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
        signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25">
        <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; border-collapse: separate; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">

            <tr>
              <td valign="top" style="width: 50%;">&#160;</td>
              <td valign="top" colspan="2">MEDIWOUND LTD.</td>
              <td valign="top" style="width: 12%;">&#160;</td>
            </tr>
            <tr>
              <td valign="top" style="width: 50%;">&#160;</td>
              <td valign="top" style="width: 4%;">&#160;</td>
              <td valign="top" style="width: 34%;">&#160;</td>
              <td valign="top" style="width: 12%;">&#160;</td>
            </tr>
            <tr>
              <td valign="top" align="left" style="width: 50%; padding-bottom: 2px;">Date: August 15, 2024</td>
              <td valign="top" style="width: 4%; padding-bottom: 2px;">
                <div align="left" style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt">By: </div>
              </td>
              <td valign="top" nowrap="nowrap" align="left" style="width: 34%; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Hani Luxenburg</td>
              <td valign="top" style="width: 12%; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td valign="top" style="width: 50%;">&#160;</td>
              <td valign="top" style="width: 4%;">Name:</td>
              <td valign="bottom" nowrap="nowrap" align="left" style="width: 34%;">Hani Luxenburg</td>
              <td valign="top" style="width: 12%;">&#160;</td>
            </tr>
            <tr>
              <td valign="top" style="width: 50%;">&#160;</td>
              <td valign="top" style="width: 4%;">Title:<br>
              </td>
              <td valign="top" style="width: 34%;">
                <div style="text-align: left; line-height: 1.25;">Chief Financial Officer</div>
              </td>
              <td valign="top" style="width: 12%;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXHIBIT INDEX</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">The following exhibit is filed as part of this Form 6-K:</div>
      <br>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="5bb8bc6ea1b34f05938cccf5040228ae" class="DSPFListTable">

          <tr>
            <td style="width: 72pt; vertical-align: top;"><u>Exhibit</u></td>
            <td style="width: auto; vertical-align: top; text-align: justify;"><u>Description</u></td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z565be196695e41e78785e513a0a2a38f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top;"><a href="exhibit_99-1.htm">99.1</a></td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><a href="exhibit_99-1.htm">Press release dated August 15, 2024 entitled &#8220;MediWound
                  Announces U.S. Food and Drug Administration Approval of NexoBrid&#174; for the Treatment of Pediatric Patients with Severe Thermal Burns&#8221;.</a></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
  </div>
  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">4</font>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 24.6.1.5240
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br>
    </div>
    <div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25;"><img src="image00001.jpg"></div>
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">MediWound Announces U.S. Food and Drug Administration Approval of </div>
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">NexoBrid<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> for the Treatment of Pediatric Patients with Severe Thermal Burns</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">Approval Helps Solidify NexoBrid&#8217;s Position in the U.S. as a Safe and Effective Non-Surgical Burn </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">Treatment for All Ages</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">YAVNE, Israel, August 15, 2024</font>
        -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for NexoBrid<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>(anacaulase-bcdb)
        allowing for eschar removal in pediatric patients aged newborn through eighteen with deep partial- and/or full-thickness thermal burns. With this FDA approval, NexoBrid is now authorized for use in the U.S. for all age groups, aligning with its
        approvals in the European Union and Japan.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;Today's announcement marks a significant milestone in our mission to improve burn care with NexoBrid,&#8221; said Ofer Gonen, Chief
        Executive Officer of MediWound. &#8220;Pediatric burn victims represent over 30% of the total burn population, and the current surgical standard of care can be extremely traumatic for both patients and their families. Since NexoBrid's initial approval,
        we have been dedicated to expanding its use to children, reflecting our long-term commitment to revolutionizing burn care.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The submission was supported by the results of a global
          Phase III clinical trial, Children Innovation Debridement Study (CIDS), which evaluated the safety and efficacy of NexoBrid in hospitalized pediatric patients, as well as additional pediatric data available from Phase III and Phase II studies
          conducted during the clinical development of NexoBrid. Of note, the CIDS trial was funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR)
        within the U.S. Department of Health and Human Services.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About NexoBrid<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">NexoBrid<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in
          patients with deep partial and/or full-thickness thermal burns without harming viable tissue. NexoBrid<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is approved in over 40 countries, including the United States, European Union, and Japan. It has been designated as an orphan
          biologic drug in all these territories.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25;">NexoBrid development has been supported in whole or in part with federal funds from the U.S. Department of Health and Human
          Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract HHSO100201500035C. This contract provided funding and technical support for the pivotal U.S. Phase 3
          clinical study (DETECT), the randomized, controlled pivotal clinical trial for use in the pediatric population (CIDS), the marketing approval registration process for NexoBrid as well as its procurement and availability under the expanded access
          treatment protocol (NEXT). Additional projects for evaluation of NexoBrid funded under the BARDA contract include establishment of a pre-emergency use data package and development of the health economic model to evaluate the cost savings impact
          to enable market adoption in the United States.</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About&#160;MediWound</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair.
        The Company specializes in the development, production and commercialization of rapid and effective biologics that improve existing standards of care and patient experiences, while reducing costs and unnecessary surgeries.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">MediWound&#8217;s first drug, NexoBrid<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, is an FDA and EMA-approved orphan biologic for eschar removal in deep partial-thickness
        and/or full-thickness thermal burns, which can significantly reduce surgical interventions. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&amp;D pipeline, including the company&#8217;s lead drug
        under development, EscharEx<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>. EscharEx<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is a Phase III-ready biologic for the debridement of chronic wounds, offering significant potential advantages over the dominant $360+ million product and an opportunity to expand the
        market.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">For more information visit <u>www.mediwound.com</u>
        and follow the Company on <u>LinkedIn</u>.</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Cautionary Note Regarding Forward-Looking Statements</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25;"><font style="font-style: italic;">MediWound&#160;cautions you that
              all statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect,&#160;believe,&#160;or anticipate will or may occur in the future are forward-looking
              statements.&#160;Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current&#160;expectations about future events affecting us and are subject to risks,
              assumptions,&#160;uncertainties,&#160;and factors, all of which are difficult to predict and many of which are beyond our control.&#160; Actual results may differ materially from those expressed or implied by the forward-looking statements in this press
              release.&#160; These statements are often, but are not always, made through the use of words or phrases such as &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;continues,&#8221; &#8220;believe,&#8221; &#8220;guidance,&#8221; &#8220;outlook,&#8221; &#8220;target,&#8221; &#8220;future,&#8221;
              &#8220;potential,&#8221; &#8220;goals&#8221; and similar words or phrases, or future or conditional verbs such as &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; or similar expressions</font>. <font style="font-style: italic;">Specifically, this press release contains
              forward-looking statements concerning&#160;the anticipated progress, development, study design, expected data timing, objectives anticipated timelines, expectations and commercial potential of our products and product candidates,
              including&#160;NexoBrid. Among the factors that may cause results to be materially different from those stated herein are the inherent uncertainties associated with the uncertain, lengthy and expensive nature of the product development process;
              the timing and conduct of our studies of our products and product candidates, including the timing, progress and results of current and future clinical studies, and our research and development programs; the approval of regulatory submission
              by the FDA, the European Medicines Agency or by any other regulatory authority, our ability to obtain marketing approval of our products and product candidates in the U.S. or other markets; the clinical utility, potential advantages and
              timing or likelihood of regulatory filings and approvals of our products and products; our expectations regarding future growth, including our ability to develop new products; market acceptance of our products and product candidates; our
              ability to maintain adequate protection of our intellectual property; competition risks; the need for additional financing; the impact of government laws and regulations and the impact of the current global macroeconomic climate on our
              ability to source supplies for our operations or our ability or capacity to manufacture, sell and support the use of our products and product candidates in the future. These and other significant factors are discussed in greater detail in MediWound&#8217;s annual report on
            Form 20-F for the year ended&#160;December 31, 2023, filed with the&#160;Securities and Exchange Commission&#160;(&#8220;SEC&#8221;) on&#160;March 21, 2024 and Quarterly Reports on Form 6-K and other filings with the&#160;SEC&#160;from time-to-time. These forward-looking statements
            reflect MediWound&#8217;s current views as of the date hereof and&#160;MediWound&#160;undertakes, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or
            circumstances that occur after the date of this release except as required by law.</font></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; font-weight: bold;">MediWound Contacts:</div>
        <div style="line-height: 1.25; font-weight: bold;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="zdd17ab3eb1484fbf842392ff5834139b">

              <tr>
                <td style="width: 50.00%;">Hani Luxenburg</td>
                <td style="width: 50.00%;">Daniel Ferry</td>
              </tr>
              <tr>
                <td style="width: 50.00%;" rowspan="1">Chief Financial Officer <br>
                </td>
                <td style="width: 50.00%;" rowspan="1">Managing Director</td>
              </tr>
              <tr>
                <td style="width: 50.00%;" rowspan="1">MediWound Ltd.</td>
                <td style="width: 50.00%;" rowspan="1">LifeSci Advisors, LLC</td>
              </tr>
              <tr>
                <td style="width: 50.00%;" rowspan="1"><u>ir@mediwound.com</u></td>
                <td style="width: 50.00%;" rowspan="1"><u>daniel@lifesciadvisors.com</u></td>
              </tr>
              <tr>
                <td style="width: 50.00%;" rowspan="1"><br>
                </td>
                <td style="width: 50.00%;" rowspan="1"><br>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Media Contact:&#160;</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">Ellie Hanson<br>
          FINN Partners for MediWound</div>
        <div style="line-height: 1.25;"><u>ellie.hanson@finnpartners.com</u></div>
        <div style="line-height: 1.25;">+1-929-588-2008</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div class="BRPFPageFooter">
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25;">
            <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !4 .,# 2(  A$! Q$!_\0
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%** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
